Assessing The Utility Of Circulating Cell-free MicroRNA As Biomarkers For Response In A Variety Of Non Hodgkin Lymphomas
Funder
National Health and Medical Research Council
Funding Amount
$92,159.00
Summary
Non Hodgkin Lymphomas are the most common blood cancer to affect adult Australians. The current strategies for diagnosis, treatment and monitoring of these patients are generic and not tailored to features of particular patientÍs lymphoma or treatment response. We aim to develop a new blood based marker for Lymphoma that can be used to diagnose and monitor NHL patients, to allow treatment to be adjusted according the patients current response to therapy, as indicated by the blood based marker. T
Defining The Myb-p300 Dependent Transcriptional Program In Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$603,632.00
Summary
MYB is a “cancer gene” which turns other genes on or off. MYB is needed by leukaemia cells but also for normal blood cell formation. We have found that interaction between the MYB protein and a protein called p300 is more critical for growth of leukaemia cells than for normal cells. Here we aim to identify a set of MYB/p300 co-regulated genes that are needed by leukaemia cells for the continued growth or survival. Some of these genes may be targets for developing new leukaemia drugs.